Multidimensional regulation of the opioid network by ACKR3
Early stage researcher 16 (ESR16) project (not funded by MSCA-ITN)
Supervision: Dr. Martyna Szpakowska, Dr. Andy Chevigné
Host: Luxembourg Institute of Health (LIH)
I – Project proposal:
Aim:
The aim of this project is to investigate the multidimensional regulatory roles that ACKR3 exerts on the opioid network, as so far little is known on the newly uncovered interconnection between the chemokine and opioid systems.
Methodology:
The project will focus on the three main levels (extracellular, intracellular and plasma membrane) of opioid system regulation by ACKR3. NanoBiT, NanoBRET and HiBiT technologies will be used to investigate the crosstalk, interconnections, compartmentalisation and regulation of the interactions between ACKR3 and classical opioid receptors and/or their ligands. The functional effect of the interactions on opioid receptor biology will also be characterized by ligand binding competition studies, GPCR-heterodimer identification technology and cellular assays and ex vivo models. Drug screening efforts will also be undertaken to find modulators capable of modulating ACKR3.
Planned secondments:
Potential collaborations of interest are to be determined.
References:
The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides. Szpakowska, M*, Meyrath, M*, Zeiner, J, L., M, Merz, M, Benkel, T., Simon, K., Ohnmacht, J., Turner, J., Krüger, R, Seutin, V, Ollert, M, Kostenis E and Chevigné, A. Nature Comm., 2020 11(1):3033. (*equally contributed).
Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists. Szpakowska M*, Meyrath M*, Reynders N, Counson M, Hanson J, Steyaert J, Chevigné A. Biochem Pharmacol. 2018 Jul;153:299-309. (*equally contributed).
Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3. Szpakowska M*, Nevins AM*, Meyrath M, Rhainds D, D’huys T, Guité-Vinet F, Dupuis N, Gauthier PA, Counson M, Kleist A, St-Onge G, Hanson J, Schols D, Volkman BF, Heveker N, Chevigné A. Br J Pharmacol. 2018 May;175(9):1419-1438. (*equally contributed).
Follow us on
My project will be focused on the role of #CXCR4/ACKR3/GRK2 -governed networks in cancer cell migration and metastasis.
New review on #gpcr structural dynamics out in COSB. Great teamwork with the @JanaSelent group. Thanks to @Lundbeckfonden and @novonordiskfond https://lnkd.in/eyjrA5V
A reminder that applications for our new Deputy Editor in Chief of #PharmacologyMatters close on Monday. https://buff.ly/2PNWf4V
ONCORNET2.0 is the successor to #ONCORNET. You can see some of the work of ESRs from the first ONCORNET in this special issue of @MolPharmJournal from 2019, with reviews on #CXCR4 and #ACKR3 structure and function: https://molpharm.aspetjournals.org/content/96/6
Hi everyone – we’re on Twitter! ONCORNET2.0 is a #MarieCurie ITN of 16 ESRs across Europe studying #chemokine #GPCRs #CXCR4 and #ACKR3 in cancer. Our projects cover molecular dynamics, medchem, #pharmacology through to translational work. Follow us for updates from our ESRs!
Contact details
Please contact us at:
info@oncornet.eu
ONCORNET Coordinator
VU University Amsterdam
The Netherlands